Table III.
Clinical and biochemical characteristics.
| Parameter | Healthy controls, n=50 | Patients with NAFLD, n=50 | P-value |
|---|---|---|---|
| Sex | |||
| Male | 36 (72%) | 39 (78%) | |
| Female | 14 (28%) | 11 (22%) | |
| Age, years | 42.60±1.67 | 42.24±1.50 | 0.8727 |
| AST, U/l | 22.95±0.84 | 26.63±1.23 | 0.0153 |
| ALP, U/l | 79.55±2.56 | 78.59±2.66 | 0.7958 |
| GGT, U/l | 25.60±1.94 | 50.38±6.10 | 0.0002 |
| LDH, U/l | 164.50±2.98 | 175.00±3.47 | 0.0231 |
| CK, U/l | 115.70±13.72 | 118.20±14.64 | 0.9060 |
| HBDH, U/l | 106.30±3.79 | 103.00±2.37 | 0.5102 |
| TBIL, µmol/l | 13.44±0.60 | 12.64±0.62 | 0.3536 |
| TC, µmol/l | 4.89±0.12 | 5.09±0.15 | 0.2961 |
| TG, µmol/l | 1.40±0.11 | 2.47±0.37 | 0.0061 |
| HDL, µmol/l | 1.27±0.03 | 1.15±0.04 | 0.0272 |
| LDL, µmol/l | 3.19±0.10 | 3.27±0.10 | 0.5662 |
| Lpa, mg/l | 210.10±41.60 | 126.00±23.25 | 0.1154 |
| TP, g/l | 73.13±0.75 | 71.71±0.52 | 0.1211 |
| ALB, g/l | 45.73±0.42 | 45.01±0.34 | 0.1871 |
| GLB g/l | 27.90±0.45 | 26.70±0.45 | 0.0638 |
| A/G | 1.66±0.03 | 1.71±0.04 | 0.2861 |
| GLU0, mmol/l | 5.55±0.19 | 5.69±0.32 | 0.7048 |
| Urea, mmol/l | 5.36±0.16 | 5.16±0.17 | 0.4004 |
| Cr, µmol/l | 69.32±1.54 | 68.17±1.63 | 0.6099 |
| UA, µmol/l | 328.60±9.25 | 373.30±13.46 | 0.0074 |
Data are presented as the mean ± SD. AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; LDH, lactate dehydrogenase; CK, creatine kinase; HBDH, hydroxybutyrate dehydrogenase; TBIL, total bilirubin; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lpa, lipoprotein a; TP, total protein; ALB, albumin; GLB, globulin; A/G, albumin/globulin; GLU0, fasting blood-glucose; Cr, creatinine; UA, uric acid; NAFLD, non-alcoholic fatty liver disease.